Afludol, 100 mg 20 pcs.

Antiviral agent.

Specifically suppresses influenza A and B viruses associated with severe acute respiratory syndrome. By the mechanism of antiviral action refers to fusion inhibitors (fusion), interacts with hemagglutinin of the virus and prevents fusion of the lipid shell of the virus and cell membranes. It has a moderate immunomodulatory effect.

It has interferon-inducing activity, stimulates humoral and cellular immune reactions, phagocytic function of macrophages, increases resistance of the body to viral infections. It reduces the frequency of complications associated with viral infections, as well as exacerbations of chronic bacterial diseases.

Therapeutic effectiveness in viral infections is shown in reduction of general intoxication and clinical manifestations, shortening of the duration of illness, reduction of the risk of complications.

It is classified as low-toxic compound (LD₅₀ >4 g/kg). It does not have any negative effect on human body when administered orally in recommended doses.

Indications

Prevention and treatment in adults and children: influenza A and B, ARVI, severe acute respiratory syndrome (including those complicated by bronchitis, pneumonia); secondary immunodeficiency states; complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection.

Prevention of postoperative infectious complications and normalization of immune status.

Complex therapy of acute intestinal infections of rotavirus etiology in children over 3 years of age.

Pharmacological effect

Antiviral agent.

Specifically suppresses influenza A and B viruses associated with severe acute respiratory syndrome. According to the mechanism of antiviral action, it belongs to fusion inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. Has a moderate immunomodulatory effect.

It has interferon-inducing activity, stimulates humoral and cellular immune responses, the phagocytic function of macrophages, and increases the body’s resistance to viral infections. Reduces the incidence of complications associated with viral infection, as well as exacerbations of chronic bacterial diseases.

Therapeutic effectiveness for viral infections is manifested in reducing the severity of general intoxication and clinical phenomena, reducing the duration of the disease, and reducing the risk of complications.

Refers to low-toxic compounds (LD50 >4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.

Special instructions

It does not exhibit central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy individuals of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).

Active ingredient

Umifenovir

Composition

Film-coated tablets from white to white with a creamy tint, round, biconvex, rough, at the break from white to white with a greenish-yellowish or creamy tint.

1 tab. umifenovir hydrochloride 100 mg

Excipients:

lactose monohydrate – 0.1722 g,

povidone K25 (medium molecular weight polyvinyl-pyrrolidone) – 0.0064 g,

crospovidone – 0.0094 g,

colloidal silicon dioxide (aerosil) – 0.009 g,

magnesium stearate – 0.003 g.

Film shell composition:

opadry II white [lactose monohydrate – 36%, hypromellose – 28%, titanium dioxide – 26%, macrogol-4000 (polyethylene glycol 4000) – 10%] -0.012 g.

Contraindications

Children under 3 years of age; hypersensitivity to umifenovir.

Side Effects

Rarely: allergic reactions.

Recommendations for use

Inside, before meals.

Single dose (depending on age):

Age

Single dose of the drug

from 3 to 6 years

50 mg (1 tablet of 50 mg)

from 6 to 12 years

100 mg (2 tablets of 50 mg or 1 tablet of 100 mg)

over 12 years old and adults

200 mg (4 tablets of 50 mg or 2 tablets of 100 mg)

Indication

Dosage regimen

In children over 3 years of age and adults:

Nonspecific prevention during an epidemic of influenza and other acute respiratory viral infections

in a single dose 2 times a week for 3 weeks.

Nonspecific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections

in a single dose 1 time per day for 10-14 days.

Treatment of influenza and other acute respiratory viral infections

per day (every 6 hours) for 5 days.

Complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection

in a single dose 4 times in a single dose 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.

Prevention of post-operative infectious complications

in a single dose 2 days before surgery, then on days 2 and 5 after surgery.

Storage conditions

At a temperature not exceeding 25 °C. Keep out of the reach of children.

Shelf life

2 years. Do not use after the expiration date stated on the package.

Manufacturer

Tatchimpharmpreparaty, Russia